Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Antifibrinolytic Agent

Tranexamic Acid 1g IV

Brand names: Cyklokapron, Cyclo-F

Intravenous tranexamic acid is an antifibrinolytic given in orthopaedic trauma and major surgery to reduce blood loss and transfusion requirement.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It competitively blocks the lysine-binding sites on plasminogen, preventing its conversion to plasmin and thereby stabilising formed clots against fibrinolysis.

Prescribing in practice

  • Give as early as possible after significant traumatic haemorrhage, as the survival benefit falls and may reverse if administration is delayed.
  • Caution in patients with a history of thromboembolic disease, and the intravenous dose should be reduced in renal impairment as it is renally cleared.
  • Rapid intravenous injection can cause hypotension, so administer by slow injection or infusion.

Monitoring

Monitor for ongoing bleeding, blood pressure during administration, and any features of venous or arterial thrombosis.

Counselling the patient

  • This medicine helps reduce bleeding after injury or surgery.
  • Tell the team about any previous blood clots, stroke or seizures.
  • Report new leg swelling, chest pain or breathlessness.

Evidence & guidelines

The CRASH-2 trial demonstrated reduced mortality from early tranexamic acid in trauma haemorrhage, supporting its routine use.

Reference: CRASH-2 Trial (Lancet 2010); NICE NG24 (Major Trauma); NICE TA392 (Arthroplasty); Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways